Rapid CommunicationShort Communication

In Vivo Studies on Chiral Inversion and Amino Acid Conjugation of 2-[4-(3-Methyl-2-thienyl)phenyl]propionic Acid in Rats and Dogs

Tadao Konishi, Hitoshi Nishikawa, Shigeyuki Kitamura and Kiyoshi Tatsumi
Drug Metabolism and Disposition January 1999, 27 (1) 158-160;

Abstract

The relationship between chiral inversion and stereoselective amino acid conjugation of a new nonsteroidal anti-inflammatory agent,R,S-2-[4-(3-methyl-2-thienyl)phenyl]propionic acid (R,S-MTPPA) was investigated in rats and dogs. Only theS-enantiomer was found in plasma after oral administration of S-MTPPA to both species. In contrast, the R- and S-enantiomers were both detected after the dosing of R-MTPPA. In rats, the area under the curve of S-MTPPA in plasma was only 9% of that of R-MTPPA when R-MTPPA was dosed, whereas in dogs it was 2.5 times larger than that of theR-enantiomer. After administration ofR-MTPPA, both enantiomers appeared in the urine. In rats, a small amount of S-enantiomer was found in the urine, whereas in the case of dogs the amount of theS-enantiomer was larger than that of the R-enantiomer. It appears that R-MTPPA is chirally inverted to S-MTPPA in both rats and dogs, although the extent of chiral inversion is greater in dogs than in rats. In dogs, the taurine conjugate was detected in plasma, urine and feces as a major metabolite after oral administration of eitherR- or S-MTPPA. In this case, onlyS-MTPPA-taurine was detected in the urine after the administration of S-MTPPA, and it was also the main component after administration of R-MTPPA.

R,S-2-[4-(3-Methyl-2-thienyl)phenyl]propionic acid (R,S-MTPPA),1a 2-arylpropionic acid derivative, is a new, orally effective, nonsteroidal anti-inflammatory agent. The S-isomer is pharmacologically active, whereas the R-isomer is inactive in vitro. The biological activities of S-MTPPA (code: M-5011) in animal models have been reported (Murakami et al., 1996;Kataoka et al., 1997; Tobetto et al., 1997; Kido et al., 1998). In our previous article, the disposition of S-MTPPA was studied after oral administration to rats, dogs, and monkeys using the14C-labeled drug. It was confirmed that the drug was metabolized mainly by oxidation of the thiophenyl moiety in these animals and by glucuronidation of the carboxyl group in rats and monkeys. In contrast, a major urinary and fecal metabolite in dogs was identified as the taurine conjugate of R,S-MTPPA (R,S-MTPPA-TAU) by means of isolation followed by mass spectrometry and 1H NMR analyses (Konishi et al., 1998a).

It is well known that enantiomers of 2-arylpropionic acid derivatives undergo chiral inversion from R- to S-isomer (Yamaguchi and Nakamura, 1987; Caldwell et al., 1988; Baillie et al., 1989; Shirley et al., 1995). This chiral inversion is general, although variations exist among species and drugs (Lee et al., 1985; Mayer et al., 1988; Muller et al., 1990). The R- andS-enantiomers of 2-arylpropionic acid derivatives are known to have different pharmaceutical activities. For example, the inflammatory activities of the S-enantiomers of ibuprofen, naproxen, carprofen, and fenoprofen are stronger than those of theR-enantiomers in vitro (Gaut et al., 1975; Adams et al., 1976; Buttinoni et al., 1983; Kean et al., 1989). Therefore, an understanding of the extent of chiral inversion of the drugs is needed for analysis of pharmaceutical activity and toxicity. The mechanism of chiral inversion of 2-arylpropionic acid derivatives is thought to involve the CoA thioester as an intermediate (Nakamura et al., 1981). The CoA thioester is also a common intermediate of amino acid conjugation of 2-arylpropionic acid derivatives (Hutt and Caldwell, 1990; Asami et al., 1995). In this paper, we report the relationship of chiral inversion and taurine conjugation of MTPPA after administration of R- or S-MTPPA to rats and dogs.

Materials and Methods

Materials.

The enantiomers of R,S-MTPPA and their taurine and glycine conjugates were prepared at the Maruho Kyoto Research Laboratory (Kyoto, Japan) as described in a previous article (Konishi et al., 1998a).

Animals and Drug Administration.

Sprague-Dawley strain male rats, 7 to 8 weeks old (weighing 170–240 g), were purchased from Japan SLC Inc. (Shizuoka, Japan). Male beagle dogs, 7 to 9 months old (weighing 14.1–14.7 kg), were purchased from Shimidzu Jikkenzairyo Inc. (Kyoto, Japan), and were given pellet food (DS, Oriental Yeast Co. Ltd., Tokyo, Japan).

S- or R-MTPPA was suspended in 0.5% carboxymethylcellulose sodium salt solution at the concentration of 10 mg/5 ml/kg for dosing and was orally administered to rats. The dogs received oral administration of S- or R-MTPPA in the dose of 10 mg/kg in a capsule.

Determination of Enantiomers of R,S-MTPPA.

Extraction of R,SMTPPA from plasma and urine was carried out by solid-liquid extraction and liquid-liquid extraction with diethyl ether. One milliliter of plasma or urine was treated with 2 ml of 0.2 N HCl and applied to a Sep-Pak C18 column (Waters, Milford, CT), which had been pretreated with 10 ml of methanol and 10 ml of water. The column was washed with 3 ml each of water, 1% acetic acid, and 1% acetic acid:methanol (6:4, v/v) in that order. Four ml of 1% acetic acid:methanol (1:9, v/v) was used to elute R,S-MTPPA. The eluate was evaporated under a nitrogen flow. The residue was taken up in 0.3 ml of 0.2 N HCl and 3 ml of diethyl ether, and the mixture was shaken for 10 min, and then centrifuged. The supernatant was evaporated to dryness and the residue was redissolved in 100 μl of ethanol. A 20-μl aliquot of this solution was injected into the high-performance liquid chromatography (HPLC) system according to the previously reported method (Konishi et al., 1998b).

Determination of R,S-MTPPA-TAU and its enantiomers.

R,S-MTPPA-TAU from plasma, urine, and feces was determined according to the previously described method (Konishi et al., 1998a). In order to determine the enantiomers of R,S-MTPPA-TAU from urine, an aliquot of R,S-MTPPA-TAU extracted from the sample was subjected to the HPLC system according to the reported chiral direct separation method (Konishi et al., 1998b).

Results and Discussion

Plasma Concentration of R- andS-MTPPA in Rats and Dogs.

Only the S-enantiomer was detected in plasma after oral administration of S-MTPPA to male rats. The area under the curve (AUC) of S-MTPPA was 88.5 μg·h/ml. In contrast, after administration of R-MTPPA, the S-enantiomer was detected in a small amount in addition to the unchangedR-enantiomer. The AUC of S-MTPPA after dosing ofR-MTPPA was 5.1 μg·h/ml, which corresponds to 9% of that of unchanged R-MPTTA (56.0 μg·h/ml). When the plasma concentrations of unchanged enantiomer after administration ofR- and S-MTPPA were compared, theCmax values were almost the same at about 27 μg/ml. However, the T1/2 values were different, being 1.3 and 2.0 h, respectively (Fig.1). The plasma concentrations ofR- and S-enantiomers after oral administration ofR- or S-MTPPA to male dogs are also shown in Fig.1. Only the unchanged S-enantiomer was detected at each time interval after dosing of S-MTPPA. In contrast, a large amount of the S-enantiomer was detected in plasma after administration of R-MTPPA. The plasma concentration of the S-enantiomer at 8 h after dosing ofR-MTPPA reached a peak, Cmax, of 14.5 μg/ml. In this case, AUC of S-MTPPA was 397.4 μg·h/ml, which corresponds to 2.5 times that of theR-enantiomer.

Figure 1
Figure 1

Plasma concentrations of S-MTPPA (○) and R-MTPPA (•) after oral administration of 10 mg/kg S-MTPPA (A and C) or R-MTPPA (B and D) to male rats (A and B) and male dogs (C and D).

Each value represents the mean ± S.D. of five rats or three dogs.

Urinary Excretion of R- and S-MTPPA in Rats and Dogs.

The S- and R-enantiomer were both excreted in urine until 24 h after oral administration of S-MTPPA to male rats. The urinary excretion of the R- andS-enantiomer was 0.07% and 3.2% of the dose, respectively. After administration of R-MTPPA, R- andS-enantiomer was also detected in the urine, and the amount was 0.7% and 0.2% of the dose, respectively. The excretion of unchanged S-enantiomer after administration ofS-MTPPA was five times that of unchangedR-enantiomer after administration of R-MTPPA. The excretion of the S-enantiomer was 0.7% of the dose, but there was no R-enantiomer in dog urine after administration of S-MTPPA. When R-MTPPA was administered to dogs, the S-enantiomer (0.6%) was excreted in urine, in a higher amount than the unchanged R-enantiomer (0.2%).

It was detected S-MTPPA in plasma and urine after oral administration of R-MTPPA to rats. Conversely, a small amount of the R-MTPPA was detected in urine after dosing of S-MTPPA. The result shows that the inversion ofS- to R-MTPPA also occurs in rats to a small extent, besides the R- to S-inversion. Chiral inversion of R-MTPPA to the S-enantiomer seems to be faster in dogs than in rats. Tanaka et al. (1992) reported that bothR- to S- and S- toR-inversion of 2-phenylpropionic acid takes place in dogs. In this study, MTPPA was confirmed to show R- toS-inversion in dogs.

Amino Acid Conjugates of R,S-MTPPA.

Glycine and taurine conjugates were assayed in urine and feces after administration of R- or S-MTPPA to rats and dogs. The taurine conjugate of R,S-MTPPA was detected in dog urine and feces after administration of S-MTPPA in amounts corresponding to 10.9 and 13.5% of the dose, respectively (Table1). The taurine conjugate was also detected in dog urine and feces after administration ofR-MTPPA in similar amounts to those found after dosing ofS-MTPPA. In the urine of only one rat, the taurine conjugate was excreted after administration of R-MTPPA, in an amount corresponding to 0.6% of the dose. The glycine conjugate was not detected in any of the samples from rats or dogs (data not shown).

View this table:
Table 1

Excretion of taurine conjugate of R,S-MTPPA in urine and feces for 48 h after oral administration of S-MTPPA or R-MTPPA at a dose of 10 mg/kg to male rats and dogs

The plasma concentration of R,S-MTPPA-TAU after administration of each enantiomer of MTPPA to male dogs is shown in Fig. 2. The plasma concentrations after administration of either R- or S-MTPPA peaked at 8 h after administration. The Cmax ofR,S-MTPPA-TAU after the administration of R-MTPPA was 1.41 μg/ml higher than that after the administration ofS-MTPPA (0.97 μg/ml).

Figure 2
Figure 2

Plasma concentrations of R,S-MTPPA-TAU after oral administration of S-MTPPA (○) or R-MTPPA (•) at a dose of 10 mg/kg to male dogs (n = 3).

Each value represents the mean ± S.D.

Stereoselectivity of taurine conjugation of R,S-MTPPA in dogs was investigated by chiral HPLC separation of the enantiomers of R,S-MTPPA-TAU. After administration ofS-MTPPA, only the S-enantiomer of the taurine conjugate (S-MTPPA-TAU) was detected in dog urine for 48 h, in an amount corresponding to 10.3 ± 2.7% (mean ± S.D. of four experiments) of the dose. In the case ofR-MTPPA administration, S-MTPPA-TAU was mainly excreted, in an amount corresponding to 13.2 ± 2.0% of the dose, and the R-enantiomer of the conjugate was also detected in a small amount (0.5 ± 0.3%).

It was considered that R- and S-MTPPA are each transformed to the thioester, R- and S-MTPPA-CoA, which are then interinverted by epimerase as described for ibuprofen-CoA (Shieh and Chen, 1993). This may be followed by hydrolysis to R- or S-MTPPA or by conjugation with taurine to afford R- or S-MTPPA-TAU, respectively. It appears that the S-enantiomer does not convert to the S-enantiomer-CoA ester in rats, so presumably the S-enantiomer is not a suitable substrate for rat acyl-CoA synthetase (Fournel and Caldwell, 1986). However, in dogs,S-MTPPA is converted to S-MTPPA-CoA, as indicated by the appearance of S-MTPPA-TAU in the urine after administration of S-MTPPA. R-MTPPA-CoA was considered to be converted to R-MTPPA-TAU to a small extent and S-MTPPA was converted to S-MTPPA-TAU mainly via the S-MTPPA-CoA, because S-MTPPA-TAU was found mainly in the urine after administration of R- orS-MTPPA to dogs. Taurine N-acyl transferase may be selective for S-enantiomer-CoA, rather thanR-enantiomer-CoA.

Footnotes

  • Send reprint requests to: Dr. Shigeyuki Kitamura, Institute of Pharmaceutical Sciences, Hiroshima University, School of Medicine, 1-2-3, Kasumi, Minami-ku, Hiroshima 734, Japan. E-mail address: kitamura{at}pharm.hiroshima-u.ac.jp

  • Abbreviations used are::
    MTPPA
    2-[4-(3-methyl-2-thienyl)phenyl]propionic acid
    MTPPA-TAU
    2-[4-(3-methyl-2-thienyl)phenyl]propionic acid taurine conjugate
    MTPPA-CoA
    2-[4-(3-methyl-2-thienyl)phenyl]propionic acid CoA thioester
    HPLC
    high-performance liquid chromatography
    AUC
    area under the curve
    • Received May 26, 1998.
    • Accepted August 7, 1998.

References

  1. ↵
    1. Adams SS,
    2. Bresloff P,
    3. Mason CG
    (1976) Pharmacological differences between the optical isomers of ibuprofen: Evidence for metabolic inversion of (−)-isomer. J Pharm Pharmacol 28:256–257.
    OpenUrlPubMed
  2. ↵
    1. Asami M,
    2. Takasaki W,
    3. Iwabuchi H,
    4. Haruyama H,
    5. Wachi K,
    6. Terada A,
    7. Tanaka Y
    (1995) Stereospecific taurine conjugation of the trans-OH metabolite (active metabolite) of CS-670, a new 2-arylpropionic acid nonsteroidal anti-inflammatory drug, in dogs. Biol Pharm Bull 18:1584–1589.
    OpenUrlPubMed
  3. ↵
    1. Baillie TA,
    2. Adams WJ,
    3. Kaiser DG,
    4. Olanoff LS,
    5. Halstead GW,
    6. Harpootlian H,
    7. Glessen GJV
    (1989) Mechanistic studies of the metabolic chiral inversion of (R)-ibuprofen in humans. J Pharmacol Exp Ther 249:517–523.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Buttinoni A,
    2. Ferrari M,
    3. Colombo M,
    4. Ceserani R
    (1983) Biological activity of indoprofen and its optical isomers. J Pharm Pharmacol 35:603–604.
    OpenUrlPubMed
  5. ↵
    1. Caldwell J,
    2. Hutt AJ,
    3. Fournel-Gigleux S
    (1988) The metabolic chiral inversion and dispositional enantioselectivity of the 2-arylpropionic acids and their biological consequences. Biochem Pharmacol 37:105–114.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Fournel S,
    2. Caldwell J
    (1986) The metabolic chiral inversion of 2-phenylpropionic acid in rat, mouse and rabbit. Biochem Pharmacol 35:4153–4159.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Gaut ZN,
    2. Baruth H,
    3. Randall LO,
    4. Ashley C,
    5. Paulsrud JR
    (1975) Stereoisomeric relationships among anti-inflammatory activity, inhibition of platelet aggregation, and inhibition of prostaglandin synthetase. Prostaglandins 10:59–66.
    OpenUrlPubMed
  8. ↵
    1. Mulder GJ
    1. Hutt AJ,
    2. Caldwell J
    (1990) Amino acid conjugation. in Conjugation Reactions in Drug Metabolism, ed Mulder GJ (Tayler & Francis Ltd, London), pp 273–305.
  9. ↵
    1. Kataoka M,
    2. Tonooka K,
    3. Ando T,
    4. Imai K,
    5. Aimoto T
    (1997) Hydroxyl radical scavenging activity of nonsteroidal anti-inflammatory drugs. Free Rad Res 27:419–427.
    OpenUrlPubMed
  10. ↵
    1. Kean WF,
    2. Lock CJL,
    3. Rischke J,
    4. Butt R,
    5. Buchanan WW,
    6. Howard-Lock H
    (1989) Effect of R and S enantiomers of naproxen on aggregation and thromboxane production in human platelets. J Pharm Sci 78:324–327.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Kido H,
    2. Murakami N,
    3. Ito A,
    4. Kimura K,
    5. Kodera N,
    6. Doi T,
    7. Naruse T
    (1998) Anti-inflammatory, analgesic and anti-pyretic effects of d-2-[4-(3-methyl-2-thienyl)phenyl]propionic acid (M-5011), a new nonsteroidal anti-inflammatory drug, in rats and guinea pigs. Jpn J Pharmacol 76:75–86.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Konishi T,
    2. Okada S,
    3. Nishikawa H,
    4. Esumi Y,
    5. Kitamura S,
    6. Tatsumi K
    (1998a) Disposition of a new nonsteroidal anti-inflammatory agent, S-2-[4-(3-methyl-2-thienyl)phenyl]propionic acid, in rats, dogs and monkeys. Arzneim-Forsch/Drug Res 48:266–274.
    OpenUrl
  13. ↵
    1. Konishi T,
    2. Nishikawa H,
    3. Kitamura S,
    4. Tatsumi K
    (1998b) Stereoselective determination of R,S-2-[4-(3-methyl-2-thienyl)phenyl]propionic acid and its taurine conjugates in dog urine by high-performance liquid chromatography. J Chromatogr B 709:105–111.
    OpenUrlCrossRef
  14. ↵
    1. Lee EJD,
    2. Williams K,
    3. Day R,
    4. Graham G,
    5. Champion D
    (1985) Stereoselective disposition of ibuprofen enantiomers in man. Br J Clin Pharmacol 19:669–674.
    OpenUrlPubMed
  15. ↵
    1. Mayer JM,
    2. Bartolucci C,
    3. Maitre J-M,
    4. Testa B
    (1988) Metabolic chiral inversion of anti-inflammatory 2-arylpropionates: Lack of reaction in liver homogenates, and study of methine proton acidity. Xenobiotica 18:533–543.
    OpenUrlPubMed
  16. ↵
    1. Muller N,
    2. Payan E,
    3. Lapicque F,
    4. Bannwarth B,
    5. Netter P
    (1990) Pharmacological aspects of chiral nonsteroidal anti-inflammatory drugs. Fundam Clin Pharmacol 4:617–634.
    OpenUrlPubMed
  17. ↵
    1. Murakami N,
    2. Takase H,
    3. Tomita T,
    4. Iwata K,
    5. Naruse T
    (1996) Antinociceptive activity of a novel non-steroidal anti-inflammatory drug (M-5011) with low ulcerogenic effects in mice. Jpn J Pharmacol 72:29–37.
    OpenUrlPubMed
  18. ↵
    1. Nakamura Y,
    2. Yamaguchi T,
    3. Takahashi S,
    4. Hashimoto S,
    5. Iwatani K,
    6. Nakagawa Y
    (1981) Optical isomerization mechanism of R(−)-hydratropic acid derivatives. J Pharmacobio-Dyn 4:S-1.
    OpenUrl
  19. ↵
    1. Shieh W-R,
    2. Chen C-S
    (1993) Purification and characterization of novel “2-arylpropionyl-CoA epimerases” from liver cytosol and mitochondria. J Biol Chem 268:3487–3493.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Shirley MA,
    2. Guan X,
    3. Kaiser DG,
    4. Halstead GW,
    5. Baillie TA
    (1995) Taurine conjugation of ibuprofen in humans and in rat liver in vitro: Relationship to metabolic chiral inversion. J Pharmacol Exp Ther 269:1166–1175.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Tanaka Y,
    2. Shimonura Y,
    3. Hirota T,
    4. Nozaki A,
    5. Ebata M,
    6. Takasaka W,
    7. Shigehara E,
    8. Hayashi R,
    9. Caldwell J
    (1992) Formation of glycine conjugate and (−)-(R)-enantiomer from (+)-(S)-2-phenylpropionic acid suggesting the formation of the CoA thioester intermediate of (+)-(S)-enantiomer in dogs. Chirality 4:342–348.
    OpenUrlPubMed
  22. ↵
    1. Tobetto K,
    2. Yamamoto Y,
    3. Kataoka M,
    4. Ando T,
    5. Sugimoto K,
    6. Himeno M
    (1997) The effects of a newly developed nonsteroidal anti-inflammatory drug (M-5011) on arachidonic acid metabolism in rheumatoid synovial fibroblasts. Jpn J Pharmacol 75:371–379.
    OpenUrlPubMed
  23. ↵
    1. Yamaguchi T,
    2. Nakamura Y
    (1987) Stereoselective metabolism of 2-phenylpropionic acid in rat. II. Studies on the organs responsible for the optical isomerization of 2-phenylpropionic acid in rat in vivo. Drug Metab Dispos 15:535–539.
    OpenUrlAbstract
View Abstract
Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

Rapid CommunicationShort Communication

In Vivo Studies on Chiral Inversion and Amino Acid Conjugation of 2-[4-(3-Methyl-2-thienyl)phenyl]propionic Acid in Rats and Dogs

Tadao Konishi, Hitoshi Nishikawa, Shigeyuki Kitamura and Kiyoshi Tatsumi
Drug Metabolism and Disposition January 1, 1999, 27 (1) 158-160;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section